Cyclopharm Limited (ASX:CYC)

Market Cap	63.03M -47.0%
Revenue (ttm)	32.33M +17.2%
Net Income	-17.22M
EPS	-0.16
Shares Out	126.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,884
Open	0.5000
Previous Close	0.5000
Day's Range	0.4750 - 0.5200
52-Week Range	0.4700 - 1.2900
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About Cyclopharm

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1986
• Employees: 109
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CYC

Financial Performance

In 2025, Cyclopharm's revenue was 32.33 million, an increase of 17.24% compared to the previous year's 27.57 million. Losses were -17.22 million, 30.5% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 26, 2026

Data Sources Report a data error